MX2021011795A - Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble. - Google Patents
Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble.Info
- Publication number
- MX2021011795A MX2021011795A MX2021011795A MX2021011795A MX2021011795A MX 2021011795 A MX2021011795 A MX 2021011795A MX 2021011795 A MX2021011795 A MX 2021011795A MX 2021011795 A MX2021011795 A MX 2021011795A MX 2021011795 A MX2021011795 A MX 2021011795A
- Authority
- MX
- Mexico
- Prior art keywords
- double
- release
- esomeprazole
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2873—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se refiere a una composición farmacéutica que comprende esomeprazol o una sal farmacéuticamente aceptable del mismo y con un perfil de liberación doble, y particularmente a una composición farmacéutica que presenta un perfil de liberación doble de liberación inmediata y liberación sostenida para que se pueda mantener la eficacia & largo plazo. La composición farmacéutica que comprende esomeprazol o una sal farmacéuticamente aceptable del mismo y con un perfil de liberación doble, de acuerdo con la presente divulgación, puede garantizar una biodisponibilidad equivalente a la de las formulaciones existentes de esomeprazol de liberación inmediata/liberación entérica, y puede mantener la eficacia a largo plazo debido al perfil de liberación doble de la misma, incluso cuando se administra una vez al día, evitando así la aparición de acidez nocturna y, por consiguiente, se puede utilizar eficazmente como agente terapéutico para la acidez nocturna.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190038380 | 2019-04-02 | ||
PCT/KR2020/004474 WO2020204609A1 (ko) | 2019-04-02 | 2020-04-01 | 에스오메프라졸 또는 이의 약학적으로 허용 가능한 염을 포함하고 이중방출 프로파일을 갖는 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011795A true MX2021011795A (es) | 2022-01-18 |
Family
ID=72667596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011795A MX2021011795A (es) | 2019-04-02 | 2020-04-01 | Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220202795A1 (es) |
EP (1) | EP3949955A4 (es) |
KR (1) | KR102612984B1 (es) |
CN (1) | CN113597302A (es) |
BR (1) | BR112021019630A2 (es) |
MX (1) | MX2021011795A (es) |
WO (1) | WO2020204609A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102579095B1 (ko) * | 2023-03-06 | 2023-09-15 | 주식회사 중헌제약 | 에스오메프라졸 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 제형 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101084659B1 (ko) * | 2008-12-30 | 2011-11-22 | 한미홀딩스 주식회사 | 에스오메프라졸의 과립 및 그 장용성 과립의 제조방법 |
KR101378973B1 (ko) | 2012-04-13 | 2014-03-28 | 한미약품 주식회사 | 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법 |
CN104586809A (zh) * | 2015-01-08 | 2015-05-06 | 浙江亚太药业股份有限公司 | 一种埃索美拉唑镁微丸肠溶片及制备方法 |
KR101869406B1 (ko) * | 2015-11-25 | 2018-07-24 | 한국유나이티드제약 주식회사 | 방출제어형 경질캡슐 제제 |
KR101907116B1 (ko) * | 2016-07-25 | 2018-10-11 | 한미약품 주식회사 | 에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형 |
KR101877350B1 (ko) * | 2016-10-28 | 2018-08-09 | 한미약품 주식회사 | 에스오메프라졸 함유 복합 캡슐제 및 그 제조방법 |
-
2020
- 2020-04-01 BR BR112021019630A patent/BR112021019630A2/pt unknown
- 2020-04-01 CN CN202080022962.0A patent/CN113597302A/zh active Pending
- 2020-04-01 MX MX2021011795A patent/MX2021011795A/es unknown
- 2020-04-01 KR KR1020200039952A patent/KR102612984B1/ko active IP Right Grant
- 2020-04-01 EP EP20784346.7A patent/EP3949955A4/en not_active Withdrawn
- 2020-04-01 WO PCT/KR2020/004474 patent/WO2020204609A1/ko unknown
- 2020-04-01 US US17/600,639 patent/US20220202795A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020204609A1 (ko) | 2020-10-08 |
CN113597302A (zh) | 2021-11-02 |
US20220202795A1 (en) | 2022-06-30 |
KR20200116867A (ko) | 2020-10-13 |
EP3949955A1 (en) | 2022-02-09 |
EP3949955A4 (en) | 2023-01-04 |
BR112021019630A2 (pt) | 2021-12-07 |
KR102612984B1 (ko) | 2023-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119886T1 (el) | Μεθοδος βιομηχανικης κατασκευης μιας φαρμακευτικης συνθεσης στην μορφη δισκιων παρατεταμενης απελευθερωσης που περιεχουν πιρφενιδονη και χρηση αυτων στην υποστροφη χρονιας νεφρικης ανεπαρκειας, καψικης συσπασης μαστου και ηπατικης ινωσης σε ανθρωπους | |
TN2012000421A1 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
MX2015008396A (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
MX2020007552A (es) | Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio. | |
NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
WO2014016754A3 (en) | Pharmaceutical compositions of proton pump inhibitor | |
TN2015000386A1 (en) | Formulations of organic compounds | |
MX2021002277A (es) | Composicion farmaceutica que comprende agente antiplaquetario e inhibidor de la secrecion de acido gastrico. | |
MX2021011795A (es) | Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble. | |
WO2014119985A3 (es) | Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral | |
GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
MX2018000963A (es) | Composicion farmaceutica sinergica del enantiomero activo s-ketorolaco trometamina y clorhidrato de tramadol. | |
JOP20200127A1 (ar) | مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية | |
MX2022000968A (es) | Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio. | |
MX2012012410A (es) | Agente terapeutico y agente preventivo para enfermedad de alzheimer. | |
WO2012153347A3 (en) | Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate | |
WO2020013776A3 (en) | Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation | |
WO2014119984A3 (es) | Composición farmacéutica con un sistema bifásico de liberación inmediata para el control de eventos convulsivos y del dolor | |
PH12020550597A1 (en) | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt | |
IN2014CN02343A (en) | Oral formulations containing hyaluronic acid for sustained drug release | |
EP3949959A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING TRIMEBUTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USED AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER |